Heatwurx (PCSA) Competitors $0.21 0.00 (-0.61%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.20 -0.01 (-3.59%) As of 08/28/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. ENLV, SLGL, ATNF, ACRV, GBIO, PEPG, XCUR, EGRX, RENB, and HYPDShould you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include Enlivex Therapeutics (ENLV), Sol-Gel Technologies (SLGL), 180 Life Sciences (ATNF), Acrivon Therapeutics (ACRV), Generation Bio (GBIO), PepGen (PEPG), Exicure (XCUR), Eagle Pharmaceuticals (EGRX), Renovaro (RENB), and Hyperion DeFi (HYPD). These companies are all part of the "pharmaceutical products" industry. Heatwurx vs. Its Competitors Enlivex Therapeutics Sol-Gel Technologies 180 Life Sciences Acrivon Therapeutics Generation Bio PepGen Exicure Eagle Pharmaceuticals Renovaro Hyperion DeFi Enlivex Therapeutics (NASDAQ:ENLV) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Which has preferable valuation and earnings, ENLV or PCSA? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.58HeatwurxN/AN/A-$11.85M-$2.32-0.09 Is ENLV or PCSA more profitable? Enlivex Therapeutics' return on equity of -57.67% beat Heatwurx's return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% Heatwurx N/A -342.36%-243.48% Which has more volatility & risk, ENLV or PCSA? Enlivex Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Heatwurx has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Do analysts rate ENLV or PCSA? Enlivex Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 861.54%. Heatwurx has a consensus target price of $2.00, indicating a potential upside of 845.18%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Heatwurx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Heatwurx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders have more ownership in ENLV or PCSA? 1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 2.4% of Heatwurx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to ENLV or PCSA? In the previous week, Heatwurx had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Heatwurx and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.93 beat Heatwurx's score of -0.06 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heatwurx 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryEnlivex Therapeutics beats Heatwurx on 8 of the 13 factors compared between the two stocks. Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricHeatwurxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.72M$2.51B$5.78B$9.79BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-0.0922.8231.2626.59Price / SalesN/A729.20453.73167.91Price / CashN/A177.0937.7359.36Price / Book1.766.1810.046.68Net Income-$11.85M$32.94M$3.27B$265.59M7 Day Performance-2.94%-0.78%1.34%0.66%1 Month Performance-3.64%2.77%6.13%2.64%1 Year Performance-84.78%12.01%41.90%22.36% Heatwurx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAHeatwurx2.5393 of 5 stars$0.21-0.6%$2.00+845.2%-85.2%$10.72MN/A-0.0920News CoverageAnalyst DowngradeENLVEnlivex Therapeutics3.2384 of 5 stars$1.25-31.3%$10.00+700.0%-17.5%$43.04MN/A-1.8970News CoverageUpcoming EarningsGap UpHigh Trading VolumeSLGLSol-Gel Technologies0.7894 of 5 stars$16.10+4.3%$40.00+148.4%+224.0%$43.01M$11.54M-13.0950Gap UpATNF180 Life Sciences0.6649 of 5 stars$7.27-4.5%N/A+53.6%$42.52MN/A-0.487Gap DownACRVAcrivon Therapeutics3.2965 of 5 stars$1.39+3.0%$17.57+1,164.1%-85.7%$42.47MN/A-0.6258GBIOGeneration Bio3.4219 of 5 stars$6.63+5.4%$10.67+60.9%-75.8%$42.37M$19.89M-0.61150Gap DownPEPGPepGen3.3289 of 5 stars$1.30+0.8%$7.67+489.7%-87.0%$42.31MN/A-0.4430Positive NewsXCURExicure2.02 of 5 stars$6.55-1.5%N/A+1,169.2%$42.01M$500K-1.6950Positive NewsGap UpEGRXEagle Pharmaceuticals1.6986 of 5 stars$3.20flatN/A-40.6%$41.56M$257.55M0.00100News CoverageGap DownRENBRenovaro1.2123 of 5 stars$0.23-3.3%N/A-62.1%$41.15MN/A-0.3020News CoverageHYPDHyperion DeFi0.2685 of 5 stars$7.46+3.6%$2.00-73.2%-84.0%$41M$60K-0.1340 Related Companies and Tools Related Companies Enlivex Therapeutics Alternatives Sol-Gel Technologies Alternatives 180 Life Sciences Alternatives Acrivon Therapeutics Alternatives Generation Bio Alternatives PepGen Alternatives Exicure Alternatives Eagle Pharmaceuticals Alternatives Renovaro Alternatives Hyperion DeFi Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access